Id	Study	Session	StudySession	SL	TL	Task	Text	Part	SGroup	TGroup	STid	SGid	STseg	TokS	LenS	TTid	TGid	TTseg	TokT	LenT	Ins	Del	Munit	InEff	FixS	TrtS	OrtS	OrtT	MU1rtS	MU1rtT	FFTimeS	FFDurS	FixT	TrtT	FFTimeT	FFDurT	CrossS	CrossT	Pause	Dur	End	Edit	Pause1	Time1	Ins1	Del1	Dur1	End1	Edit1	Pause2	Time2	Ins2	Del2	Dur2	End2	Edit2	PauseR	TimeR	InsR	DelR	DurR	EditR	Edit
1	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	How	Wie	1	1	1	1	3	1	1	1	1	3	2	0	1	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	2995	249	24071	[_	2995	23822	1	0	0	23822	_	0	0	0	0	0	0	---	0	0	0	0	0	---	[_
2	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	does_work	wirkt	2	2+4	1	2	8	2	2	1	1	9	10	0	1	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	3	249	13572	37643	wirkt	249	24071	5	0	468	24539	wirkt[	0	0	0	0	0	0	---	0	0	0	0	0	---	wirkt
3	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	Hycamtin	Hycamtin	3	3	1	1	8	3	3	1	1	8	0	24	1	-1.0870	0	0	0	0	0	0	0	0	0	0	0	0	1	-1	19329	4493	23822	[netiebra_uz_	19329	19329	0	12	1498	20827	netiebra_uz_]	0	0	0	0	0	0	---	0	0	0	0	0	---	[netiebra_uz_
4	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	?	?	5	5	1	1	1	4	4	1	1	1	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	2	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
5	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	The	Der	6	6	2	1	3	5	5	2	1	3	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
6	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	active_substance	Wirkstoff	7	7+8	2	2	15	6	6	2	1	16	0	4	1	-1.6667	0	0	0	0	0	0	0	0	0	0	0	0	1	2	74599	437	113647	[ni	74599	113210	0	2	94	113304	ni]	0	0	0	0	0	0	---	0	0	0	0	0	---	[ni
7	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	in	von	9	9	2	1	2	7	7	2	1	2	10	4	1	2.1429	0	0	0	0	0	0	0	0	0	0	0	0	1	1	343	6334	119981	[vpn[np]on	343	113647	5	2	1607	115254	vpn[np]on[	0	0	0	0	0	0	---	0	0	0	0	0	---	[vpn[np]on
8	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	Hycamtin	Hycamtin	10	10	2	1	8	8	8	2	1	8	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
9	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	,	,	11	11	2	1	1	9	9	2	1	1	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
10	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	topotecan	Topotecan	12	12	2	1	9	10	10	2	1	9	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
11	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	,	,	13	13	2	1	1	11	11	2	1	1	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
12	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	is	ist	14	14	2	1	2	12	12	2	1	2	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
13	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	an	ein	15	15	2	1	2	13	13	2	1	2	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
14	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	anticancer	gegen_Krebs	16	16	2	1	10	15	15+16	2	2	9	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	3	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
15	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	medicine	Arzneimittel	17	17	2	1	8	14	14	2	1	8	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	-2	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
16	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	that	,_das	18	18	2	1	4	17	17+18	2	2	3	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	4	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
17	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	belongs	gehört	19	19	2	1	7	27	27	2	1	7	12	0	1	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	9	1	1622	952	639948	[gehört	0	0	0	0	0	0	---	0	0	0	0	0	0	---	1622	638996	6	0	874	gehört	[gehört
18	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	to_the	zur	20	20+21	2	2	5	19	19	2	1	6	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	-8	2	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
19	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	group	Gruppe	22	22	2	1	5	20	20	2	1	5	0	12	1	-1.1818	0	0	0	0	0	0	0	0	0	0	0	0	1	1	4727	64537	184518	[tröheg	4727	119981	0	6	1872	121853	tröheg	0	0	0	0	0	0	---	0	0	0	0	0	---	[tröheg
20	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	""""	""""	23	23	2	1	1	22	22	2	1	1	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
21	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	topoisomerase	Topoisomerase_-	24	24	2	1	13	23	23+24	2	2	12	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
22	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	inhibitors	Hemmer	25	25	2	1	10	25	25	2	1	10	0	4	1	-1.6667	0	0	0	0	0	0	0	0	0	0	0	0	1	1	7254	1747	638996	"[""."	0	0	0	0	0	0	---	0	0	0	0	0	0	---	7254	637249	0	2	125	""".]"	"[""."
23	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	.	.	26	26	2	1	1	28	28	2	1	1	2	0	1	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	3	1	78	22932	662880	.	0	0	0	0	0	0	---	0	0	0	0	0	0	---	78	639948	1	0	0	.[	.
24	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	It	Es	28	28	3	1	2	29	29	3	1	2	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	2	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
25	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	blocks	blockiert	29	29	3	1	6	30	30	3	1	6	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
26	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	an	das	30	30	3	1	2	31	31	3	1	2	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
27	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	enzyme	Enzym	31	31	3	1	6	32	32	3	1	6	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
28	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	topoisomerase	Topoisomerase	33	33	3	1	13	33	33	3	1	13	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	2	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
29	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	I	I	34	34	3	1	1	34	34	3	1	1	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
30	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	,	,	35	35	3	1	1	35	35	3	1	1	0	6	1	-1.4000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	13026	624	275373	[eid	13026	274749	0	3	266	275015	eid]	0	0	0	0	0	0	---	0	0	0	0	0	---	[eid
31	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	which	das	36	36	3	1	5	36	36	3	1	5	8	6	1	5.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	358	5336	280709	[das[ni_]_	358	275373	4	3	5133	280506	das[ni_]_	0	0	0	0	0	0	---	0	0	0	0	0	---	[das[ni_]_
32	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	is	ist	37	37	3	1	2	43	43	3	1	2	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	7	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
33	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	involved	beteiligt	38	38	3	1	8	42	42	3	1	8	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	-1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
34	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	in	an	39	39	3	1	2	37	37	3	1	2	4	0	1	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	-5	1	203	4118	284827	an	203	280709	2	0	78	280787	an[	0	0	0	0	0	0	---	0	0	0	0	0	---	an
35	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	the	der	40	40	3	1	3	38	38	3	1	3	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
36	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	division	Teilung	41	41	3	1	8	39	39	3	1	8	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
37	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	of	der	42	42	3	1	2	40	40	3	1	2	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
38	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	DNA	DNA	43	43	3	1	3	41	41	3	1	3	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
39	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	.	.	44	44	3	1	1	44	44	3	1	1	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	3	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
40	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	and	---	27	149	3	1	3	0	0	0	1	3	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	105	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
41	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	and	---	32	149	3	1	3	0	0	0	1	3	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
42	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	When	Wenn	45	45	4	1	4	45	45	4	1	4	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	-1	-104	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
43	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	the	das	46	46	4	1	3	46	46	4	1	3	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
44	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	enzyme	Enzym	47	47	4	1	6	47	47	4	1	6	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
45	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	is	wird	48	48	4	1	2	49	49	4	1	2	8	0	1	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	2	1	234	56488	341861	[wird	234	285373	4	0	390	285763	wird[	0	0	0	0	0	0	---	0	0	0	0	0	---	[wird
46	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	blocked	blockiert	49	49	4	1	7	48	48	4	1	7	0	6	1	-1.4000	0	0	0	0	0	0	0	0	0	0	0	0	-1	1	4040	546	285373	[tsi	4040	284827	0	3	312	285139	tsi]	0	0	0	0	0	0	---	0	0	0	0	0	---	[tsi
47	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	,	,	50	50	4	1	1	50	50	4	1	1	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
48	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	the	die	51	51	4	1	3	52	52	4	1	3	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
49	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	DNA	DNA_-	52	52	4	1	3	53	53+54	4	2	2	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
50	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	strands	Stränge	53	53	4	1	7	55	55	4	1	7	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
51	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	break	brechen	54	54	4	1	5	51	51	4	1	5	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	-4	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
52	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	.	.	55	55	4	1	1	56	56	4	1	1	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	5	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
53	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	This	Dies	56	56	5	1	4	57	57	5	1	4	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
54	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	prevents	verhindert	57	57	5	1	8	58	58	5	1	8	76	208	2	-2.1756	0	0	0	0	0	0	0	0	0	0	0	0	1	1	85597	47939	669260	red_na_nellezsberK_eid_ssad_,]_die_der_kREBS[SBERk]Krebszellen[,nebrets_]_absterben_[ba_hcilßeilhcs_nebrets_eis_dnu_nellezsberK_red_gnulieT_eid_tr]rt	62665	184518	36	43	25273	209791	red_na_nellezsberK_eid_ssad_,]_die_der_kREBS[SBERk]Krebszellen[,nebrets_]_absterben_[	0	0	0	0	0	0	---	22932	662880	2	61	4508	ba_hcilßeilhcs_nebrets_eis_dnu_nellezsberK_red_gnulieT_eid_tr]rt	red_na_nellezsberK_eid_ssad_,]_die_der_kREBS[SBERk]Krebszellen[,nebrets_]_absterben_[ba_hcilßeilhcs_nebrets_eis_dnu_nellezsberK_red_gnulieT_eid_tr]rt
55	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	the	die	58	58	5	1	3	62	62	5	1	3	8	0	1	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	4	1	188	530	670399	die_	0	0	0	0	0	0	---	0	0	0	0	0	0	---	188	669869	4	0	296	die_	die_
56	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	cancer_cells	Krebszellen	59	59+60	5	2	11	63	63	5	1	12	38	14	1	2.1200	0	0	0	0	0	0	0	0	0	0	0	0	1	2	234	26411	696810	Krebszellen_zeilen[neliez]w[w	0	0	0	0	0	0	---	0	0	0	0	0	0	---	234	670399	19	7	26224	Krebszellen_zeilen[neliez]w[w]	Krebszellen_zeilen[neliez]w[w
57	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	dividing	sich_teilen	62	62	5	1	8	61	61+64	5	2	7	24	0	2	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	-2	2	2059	2512	698713	sich_[teilen_	0	0	0	0	0	0	---	0	0	0	0	0	0	---	187	696810	7	0	718	teilen_	sich_[teilen_
58	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	and	und	63	63	5	1	3	66	66	5	1	3	8	0	1	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	5	1	1185	359	699072	und_	0	0	0	0	0	0	---	0	0	0	0	0	0	---	1185	698713	4	0	250	und_	und_
59	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	they	sie	64	64	5	1	4	69	69	5	1	4	8	0	1	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	3	1	109	359	705515	sie_	0	0	0	0	0	0	---	0	0	0	0	0	0	---	109	705156	4	0	281	sie_	sie_
60	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	eventually	somit	65	65	5	1	10	67	67	5	1	10	12	0	1	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	-2	1	109	1451	700523	somit_	0	0	0	0	0	0	---	0	0	0	0	0	0	---	109	699072	6	0	1201	somit_	somit_
61	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	die	sterben_ab	66	66	5	1	3	68	68+70	5	2	2	46	26	2	3.4762	0	0	0	0	0	0	0	0	0	0	0	0	3	1	328	14118	715000	sterben_sie_ab[ba_eis_nebret]terben_ab	0	0	0	0	0	0	---	0	0	0	0	0	0	---	78	705515	2	13	62	ab[	sterben_sie_ab[ba_eis_nebret]terben_ab
62	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	.	.	67	67	5	1	1	71	71	5	1	1	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
63	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	and	---	61	149	5	1	3	0	0	0	1	3	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	82	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
64	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	Hycamtin	Hycamtin	68	68	6	1	8	72	72	6	1	8	0	52	2	-1.0392	0	0	0	0	0	0	0	0	0	0	0	0	0	-81	18361	4321	254313	[-thciN_fua_hcua_hcis_tkriw	16286	226077	0	7	796	226873	-thciN_]	2075	251193	0	19	2761	253954	fua_hcua_hcis_tkriw]	0	0	0	0	0	---	[-thciN_fua_hcua_hcis_tkriw
65	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	also	auch	69	69	6	1	4	74	74	6	1	4	20	10	2	2.8182	0	0	0	0	0	0	0	0	0	0	0	0	2	1	9547	3823	717543	auch_eine_[enie_	124	254812	10	0	1014	255826	auch_eine_	0	0	0	0	0	0	---	9423	715000	0	5	515	enie_]	auch_eine_[enie_
66	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	affects	hat_Wirkungen_auf	70	70	6	1	7	73	73+75+76	6	3	5	36	0	4	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	2	1	3058	5724	718853	[_[hat_Wirkung_auf[en	405	227278	1	0	0	227278	_	359	254313	4	0	375	254688	hat_	2028	717543	2	0	1310	en	[_[hat_Wirkung_auf[en
67	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	non_-_cancer	gesunde	71	71+72+73	6	3	10	77	77	6	1	12	16	12	1	5.8000	0	0	0	0	0	0	0	0	0	0	0	0	1	3	203	6037	233518	gesunde_[zsberK	203	227481	8	6	5273	232754	gesunde_[zsberK]	0	0	0	0	0	0	---	0	0	0	0	0	---	gesunde_[zsberK
68	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	cells	Zellen	74	74	6	1	5	78	78	6	1	5	10	8	1	6.3333	0	0	0	0	0	0	0	0	0	0	0	0	1	1	764	17675	251193	[Z_aus[sua_	764	233518	5	4	15600	249118	Z_aus[sua_	0	0	0	0	0	0	---	0	0	0	0	0	---	[Z_aus[sua_
69	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	,	,	75	75	6	1	1	79	79	6	1	1	0	6	1	-1.4000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	2402	1358	261162	[eid	2402	259804	0	3	1061	260865	eid]	0	0	0	0	0	0	---	0	0	0	0	0	---	[eid
70	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	which	was	76	76	6	1	5	80	80	6	1	5	8	0	1	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	297	13587	274749	[was_	297	261162	4	0	561	261723	was_[	0	0	0	0	0	0	---	0	0	0	0	0	---	[was_
71	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	causes	verursacht	77	77	6	1	6	83	83	6	1	6	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	3	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
72	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	side_effects	Nebenwirkungen	78	78+79	6	2	11	82	82	6	1	12	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	-1	2	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
73	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	.	.	80	80	6	1	1	84	84	6	1	1	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
74	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	How	Wie	81	81	7	1	3	85	85	7	1	3	0	6	1	-1.4000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	13104	422	38065	[tah	13104	37643	0	3	234	37877	tah]	0	0	0	0	0	0	---	0	0	0	0	0	---	[tah
75	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	has_been	wurde	82	82+84	7	2	7	86	86	7	1	8	10	0	1	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	3	188	75145	113210	[wurde	188	38065	5	0	546	38611	wurde[	0	0	0	0	0	0	---	0	0	0	0	0	---	[wurde
76	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	Hycamtin	Hycamtin	83	83	7	1	8	87	87	7	1	8	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	-1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
77	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	studied	untersucht	85	85	7	1	7	88	88	7	1	7	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	2	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
78	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	?	?	86	86	7	1	1	89	89	7	1	1	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
79	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	Hycamtin	Hycamtin	87	87	8	1	8	90	90	8	1	8	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
80	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	as	als	88	88	8	1	2	91	91	8	1	2	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
81	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	infusion	Infusion	90	90	8	1	8	92	92	8	1	8	0	30	1	-1.0690	0	0	0	0	0	0	0	0	0	0	0	0	1	2	56098	5741	347602	[_ni_tahsla_rhem	56098	341861	0	15	5304	347165	_ni_tahsla_rhem]	0	0	0	0	0	0	---	0	0	0	0	0	---	[_ni_tahsla_rhem
82	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	has_been	wurde	91	91+92	8	2	7	93	93	8	1	8	12	0	1	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	2	437	889	348491	[wurde_	437	347602	6	0	686	348288	wurde_	0	0	0	0	0	0	---	0	0	0	0	0	---	[wurde_
83	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	studied	untersucht	93	93	8	1	7	100	100	8	1	7	20	2	1	1.2105	0	0	0	0	0	0	0	0	0	0	0	0	7	1	296	8378	371720	untersucht[_	296	363342	10	1	3120	366462	untersucht[_	0	0	0	0	0	0	---	0	0	0	0	0	---	untersucht[_
84	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	in	an	94	94	8	1	2	94	94	8	1	2	6	0	1	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	-6	1	203	343	348834	an_	203	348491	3	0	203	348694	an_	0	0	0	0	0	0	---	0	0	0	0	0	---	an_
85	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	more_than	über	95	95+96	8	2	8	95	95	8	1	9	8	0	1	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	2	140	14212	363046	über	140	348834	4	0	499	349333	über	0	0	0	0	0	0	---	0	0	0	0	0	---	über
86	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	480	480	97	97	8	1	3	96	96	8	1	3	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
87	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	women	Frauen	98	98	8	1	5	97	97	8	1	5	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
88	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	with	mit	99	99	8	1	4	98	98	8	1	4	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
89	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	ovarian_cancer	Eierstockkrebs	100	100+101	8	2	13	99	99	8	1	14	2	0	1	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	2	13713	296	363342	_	13713	363046	1	0	0	363046	_	0	0	0	0	0	0	---	0	0	0	0	0	---	_
90	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	who	,_bei_denen	102	102	8	1	3	101	101+102+103	8	3	1	20	16	1	7.4000	0	0	0	0	0	0	0	0	0	0	0	0	4	1	18689	2995	401126	[enie_eid]bei_denen_	18689	398131	10	8	2340	400471	enie_eid]bei_denen_	0	0	0	0	0	0	---	0	0	0	0	0	---	[enie_eid]bei_denen_
91	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	had	war	103	103	8	1	3	112	112	8	1	3	0	38	1	-1.0541	0	0	0	0	0	0	0	0	0	0	0	0	9	1	5258	6224	377944	._nedrow_thcusretnu_	5258	371720	0	19	5163	376883	._nedrow_thcusretnu_]	0	0	0	0	0	0	---	0	0	0	0	0	---	._nedrow_thcusretnu_
92	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	failed	fehlgeschlagen	104	104	8	1	6	111	111	8	1	6	34	4	1	1.2581	0	0	0	0	0	0	0	0	0	0	0	0	-1	1	296	19391	433480	fehlgeschlafe[ef]gen_	296	414089	17	2	2730	416819	fehlgeschlafe[ef]gen_[	0	0	0	0	0	0	---	0	0	0	0	0	---	fehlgeschlafe[ef]gen_
93	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	one	eine	105	105	8	1	3	104	104	8	1	3	8	0	1	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	-7	1	655	10920	412046	eine	655	401126	4	0	234	401360	eine[	0	0	0	0	0	0	---	0	0	0	0	0	---	eine
94	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	treatment	Behandlung	106	106	8	1	9	105	105	8	1	9	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
95	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	with	mit	107	107	8	1	4	106	106	8	1	4	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
96	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	platinum_-_containing	platinhaltigen	108	108+109+110	8	3	19	107	107	8	1	21	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	3	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
97	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	anticancer	gegen_Krebs	111	111	8	1	10	109	109+110	8	2	9	2	28	1	-1.2400	0	0	0	0	0	0	0	0	0	0	0	0	3	1	10686	2043	414089	[_tretiehcseg_,]_	10686	412046	1	14	1747	413793	_tretiehcseg_,]_	0	0	0	0	0	0	---	0	0	0	0	0	---	[_tretiehcseg_,]_
98	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	medicines	Arzneimitteln	112	112	8	1	9	108	108	8	1	9	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	-2	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
99	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	.	.	113	113	8	1	1	113	113	8	1	1	4	0	1	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	5	1	1061	20187	398131	[._	1061	377944	2	0	1498	379442	._[	0	0	0	0	0	0	---	0	0	0	0	0	---	[._
100	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	and	---	89	149	8	1	3	0	0	0	1	3	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	36	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
101	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	Three	Drei	114	114	9	1	5	114	114	9	1	5	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	0	-35	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
102	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	studies	Studien	115	115	9	1	7	115	115	9	1	7	0	10	1	-1.2222	0	0	0	0	0	0	0	0	0	0	0	0	1	1	16661	999	434479	[neies	16661	433480	0	5	843	434323	neies]	0	0	0	0	0	0	---	0	0	0	0	0	---	[neies
103	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	were	waren	116	116	9	1	4	116	116	9	1	4	10	0	1	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	156	31606	466085	[waren	156	434479	5	0	624	435103	waren[	0	0	0	0	0	0	---	0	0	0	0	0	---	[waren
104	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	""""	""""	117	117	9	1	1	117	117	9	1	1	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
105	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	open	offene	118	118	9	1	4	118	118	9	1	4	6	36	1	-1.4828	0	0	0	0	0	0	0	0	0	0	0	0	1	1	38595	9547	521418	"[,tetuedeb_saw_,""]e2[2]2[2"	38595	511871	3	18	7379	519250	",tetuedeb_saw_,""]e2[2]2[2]"	0	0	0	0	0	0	---	0	0	0	0	0	---	"[,tetuedeb_saw_,""]e2[2]2[2"
106	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	,	,	119	119	9	1	1	121	121	9	1	1	4	0	1	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	3	1	5101	21232	548375	,_	5101	527143	2	0	234	527377	,_	0	0	0	0	0	0	---	0	0	0	0	0	---	,_
107	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	""""	""""	120	120	9	1	1	119	119	9	1	1	4	0	1	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	-2	1	2168	5725	527143	"[""_"	2168	521418	2	0	624	522042	"""_"	0	0	0	0	0	0	---	0	0	0	0	0	---	"[""_"
108	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	the	das	123	123	9	1	3	124	124	9	1	3	8	0	1	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	5	3	20998	718	549093	das_	20998	548375	4	0	453	548828	das_	0	0	0	0	0	0	---	0	0	0	0	0	---	das_
109	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	medicine	Medikament	124	124	9	1	8	125	125	9	1	8	32	10	1	1.8696	0	0	0	0	0	0	0	0	0	0	0	0	1	1	265	14929	564022	Madika[akida]edikament_	265	549093	16	5	3603	552696	Madika[akida]edikament_	0	0	0	0	0	0	---	0	0	0	0	0	---	Madika[akida]edikament_
110	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	was	wurde	125	125	9	1	3	132	132	9	1	3	10	0	1	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	7	1	140	27223	591385	wurde	140	564162	5	0	515	564677	wurde	0	0	0	0	0	0	---	0	0	0	0	0	---	wurde
111	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	not	nicht	126	126	9	1	3	126	126	9	1	3	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	-6	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
112	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	compared	verglichen	127	127	9	1	8	131	131	9	1	8	2	0	1	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	5	1	11326	140	564162	_	11326	564022	1	0	0	564022	_	0	0	0	0	0	0	---	0	0	0	0	0	---	_
113	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	to	mit	128	128	9	1	2	127	127	9	1	2	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	-4	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
114	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	any	einer	129	129	9	1	3	128	128	9	1	3	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
115	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	other	anderen	130	130	9	1	5	129	129	9	1	5	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
116	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	treatment	Behandlung	131	131	9	1	9	130	130	9	1	9	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
117	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	and	und	132	132	9	1	3	133	133	9	1	3	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	3	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
118	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	the	die	133	133	9	1	3	136	136	9	1	3	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	3	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
119	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	patients	Patienten	134	134	9	1	8	137	137	9	1	8	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
120	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	knew	wussten	135	135	9	1	4	138	138	9	1	4	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
121	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	that	,_dass	136	136	9	1	4	139	139+140	9	2	3	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
122	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	they	sie	137	137	9	1	4	141	141	9	1	4	2	22	1	-1.3158	0	0	0	0	0	0	0	0	0	0	0	0	1	1	30982	6130	472215	[_netleihre_]_	30982	466085	1	11	2012	468097	_netleihre_]_	0	0	0	0	0	0	---	0	0	0	0	0	---	[_netleihre_]_
123	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	were_receiving	erhielten	138	138+139	9	2	13	143	143	9	1	14	18	0	1	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	2	2	219	39437	511871	erhielten	219	472434	9	0	842	473276	erhielten[	0	0	0	0	0	0	---	0	0	0	0	0	---	erhielten
124	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	Hycamtin	Hycamtin	140	140	9	1	8	142	142	9	1	8	2	0	1	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	-1	1	4118	219	472434	_	4118	472215	1	0	0	472215	_	0	0	0	0	0	0	---	0	0	0	0	0	---	_
125	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	.	.	141	141	9	1	1	144	144	9	1	1	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
126	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	and	---	121	149	9	1	3	0	0	0	1	3	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	8	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
127	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	and	---	122	149	9	1	3	0	0	0	1	3	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
128	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	The	Die	142	142	10	1	3	145	145	10	1	3	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	-1	-7	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
129	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	fourth	vierte	143	143	10	1	6	146	146	10	1	6	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
130	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	study	Studie	144	144	10	1	5	147	147	10	1	5	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
131	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	involved	umfasste	145	145	10	1	8	148	148	10	1	8	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
132	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	226	226	146	146	10	1	3	149	149	10	1	3	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
133	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	women	Frauen	147	147	10	1	5	150	150	10	1	5	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
134	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	compared	verglichen_wurde	150	150	10	1	8	164	164+165	10	2	7	32	0	1	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	15	3	296	32542	624223	verglichen_wurde	296	591681	16	0	2028	593709	verglichen_wurde[	0	0	0	0	0	0	---	0	0	0	0	0	---	verglichen_wurde
135	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	Hycamtin	Hycamtin	151	151	10	1	8	154	154	10	1	8	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	-11	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
136	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	with	mit	152	152	10	1	4	155	155	10	1	4	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
137	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	paclitaxel	Paclitaxel	153	153	10	1	10	156	156	10	1	10	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
138	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	(	(	154	154	10	1	1	157	157	10	1	1	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
139	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	another	ein_anderes	155	155	10	1	7	158	158+159	10	2	6	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
140	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	anticancer	gegen_Krebs	156	156	10	1	10	161	161+162	10	2	9	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	3	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
141	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	medicine	Arzneimittel	157	157	10	1	8	160	160	10	1	8	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	-2	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
142	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	)	)	158	158	10	1	1	163	163	10	1	1	2	0	1	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	3	1	26708	296	591681	_	26708	591385	1	0	0	591385	_	0	0	0	0	0	0	---	0	0	0	0	0	---	_
143	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	.	.	159	159	10	1	1	166	166	10	1	1	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	3	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
144	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	and	---	148	149	10	1	3	0	0	0	1	3	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	-10	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
145	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	The	Der	160	160	11	1	3	167	167	11	1	3	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	0	11	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
146	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	main_measure	Hauptindikator	161	161+162	11	2	11	168	168	11	1	12	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	2	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
147	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	of	für	163	163	11	1	2	169	169	11	1	2	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
148	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	effectiveness	Wirksamkeit	164	164	11	1	13	171	171	11	1	13	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
149	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	was	war	165	165	11	1	3	172	172	11	1	3	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
150	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	the	die	166	166	11	1	3	173	173	11	1	3	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
151	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	number	Anzahl	167	167	11	1	6	174	174	11	1	6	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
152	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	of	der	168	168	11	1	2	175	175	11	1	2	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
153	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	patients	Patienten	169	169	11	1	8	176	176	11	1	8	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
154	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	whose	,_deren	170	170	11	1	5	177	177+178	11	2	4	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
155	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	tumours	Tumore	171	171	11	1	7	179	179	11	1	7	0	2	1	-3.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	30514	3042	627265	[n	30514	624223	0	1	0	624223	n	0	0	0	0	0	0	---	0	0	0	0	0	---	[n
156	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	responded	ansprachen	172	172	11	1	9	183	183	11	1	9	18	4	1	1.5333	0	0	0	0	0	0	0	0	0	0	0	0	4	1	3042	2730	629995	.]sprache.[.]n	3042	627265	9	2	2574	629839	.]sprache.[.]n	0	0	0	0	0	0	---	0	0	0	0	0	---	.]sprache.[.]n
157	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	to	auf	173	173	11	1	2	180	180	11	1	2	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	-3	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
158	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	treatment	Behandlung	174	174	11	1	9	182	182	11	1	9	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
159	OCT13	P19_PF03	OCT13@P19_PF03	en	de	PF	03	P19	.	.	175	175	11	1	1	184	184	11	1	1	2	0	1	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	2	1	156	7254	637249	.	156	629995	1	0	0	629995	.[	0	0	0	0	0	0	---	0	0	0	0	0	---	.